← Leaderboards
Yuan T Chen
Duke University
$792,683
Attributed
$792,683
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$792,683 · 3
By mechanism
M01$644,135 · 2
F32$148,548 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Dwight D Koeberl$10,403,079
- Priya S. Kishnani$1,826,678
- Priya S Kishnani$685,042
- Nenad Bursac$22,509,345
- Kathryn R Nightingale$16,760,750
Others in their field
Top investigators on “Recombinant Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$132,165,789
- Barton F Haynes · Duke University$119,908,001
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Larry Arthur$44,832,982
- John P Moore · Weill Medical College Of Cornell Univ$36,733,380
- Wayne A. Hendrickson · Rutgers The St Univ Of Nj New Brunswick$34,072,238
Research focus
Recombinant ProteinsHuman SubjectAlpha GlucosidaseHuman Therapy EvaluationGlycogen Storage Disease Type IiClinical ResearchEnzyme TherapyFibroblastsGene MutationGenetic SusceptibilityGenotypeGlycogen Storage Disease Type IDiet TherapyGlycogen Storage Disease Type IiiDisease /Disorder EtiologyNutrition Related TagKidney DisorderPhenotypeMolecular PathologyVoltage Gated ChannelAxonGene ExpressionGene TargetingGenetically Modified Animals
Grant awards (11)
Functional role of Na+ channel beta subunits in vivo$52,492
F32 · FY2004 · NS
Functional role of Na+ channel beta subunits in vivo$49,864
F32 · FY2003 · NS
MOLECULAR MECHANISM IN TYPE III GLYCOGEN STORAGE DISEASE$117,022
M01 · FY2002 · RR
Functional role of Na+ channel beta subunits in vivo$46,192
F32 · FY2002 · NS
MOLECULAR MECHANISM IN TYPE III GLYCOGEN STORAGE DISEASE$293,069
M01 · FY2001 · RR
MOLECULAR MECHANISM IN TYPE III GLYCOGEN STORAGE DISEASE$117,022
M01 · FY2001 · RR
MOLECULAR MECHANISM IN TYPE III GLYCOGEN STORAGE DISEASE$117,022
M01 · FY2001 · RR
MOLECULAR MECHANISM IN TYPE III GLYCOGEN STORAGE DISEASE$0
M01 · FY2000 · RR
Phase I/II trial rhGAA in infantile onset Pompe disease$0
M01 · FY2000 · RR
Phase I/II trial rhGAA in infantile onset Pompe disease$0
M01 · FY2000 · RR
MOLECULAR MECHANISM IN TYPE III GLYCOGEN STORAGE DISEASE$0
M01 · FY2000 · RR